JO3371B1 - ناهضات مستقبل فاسوبريسين 2 - Google Patents

ناهضات مستقبل فاسوبريسين 2

Info

Publication number
JO3371B1
JO3371B1 JOP/2014/0234A JOP20140234A JO3371B1 JO 3371 B1 JO3371 B1 JO 3371B1 JO P20140234 A JOP20140234 A JO P20140234A JO 3371 B1 JO3371 B1 JO 3371B1
Authority
JO
Jordan
Prior art keywords
vasopressin
receptor agonists
nocturia
foregoing
methods
Prior art date
Application number
JOP/2014/0234A
Other languages
English (en)
Inventor
Riviere Pierre
Wisniewski Kazimierz
Schteingart Claudio
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JO3371B1 publication Critical patent/JO3371B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)

Abstract

ناهضات مستقبلات فاسوبريسين-2، تراكيب دوائية منها وطرق لاستخدام ما سبق ذكره لعلاج مرض السكري الكاذب و سلس البول الليلي الابتدائي وكثرة التبول أثناء الليل.
JOP/2014/0234A 2013-07-26 2014-07-24 ناهضات مستقبل فاسوبريسين 2 JO3371B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361859024P 2013-07-26 2013-07-26
US201461952073P 2014-03-12 2014-03-12

Publications (1)

Publication Number Publication Date
JO3371B1 true JO3371B1 (ar) 2019-03-13

Family

ID=51398870

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0234A JO3371B1 (ar) 2013-07-26 2014-07-24 ناهضات مستقبل فاسوبريسين 2

Country Status (28)

Country Link
US (2) US10131692B2 (ar)
EP (1) EP3024829B1 (ar)
JP (1) JP6387095B2 (ar)
KR (1) KR102198130B1 (ar)
CN (1) CN105492441B (ar)
AU (1) AU2014292860B2 (ar)
BR (1) BR112016000436B1 (ar)
CA (1) CA2919208A1 (ar)
DK (1) DK3024829T3 (ar)
EA (1) EA029392B1 (ar)
ES (1) ES2656039T3 (ar)
HK (1) HK1218647A1 (ar)
HR (1) HRP20180009T1 (ar)
HU (1) HUE035252T2 (ar)
IL (1) IL243730B (ar)
JO (1) JO3371B1 (ar)
LT (1) LT3024829T (ar)
MX (1) MX363355B (ar)
MY (1) MY183429A (ar)
PH (1) PH12016500044A1 (ar)
PL (1) PL3024829T3 (ar)
PT (1) PT3024829T (ar)
RS (1) RS56604B1 (ar)
SG (1) SG11201600031RA (ar)
SI (1) SI3024829T1 (ar)
TW (1) TWI640542B (ar)
WO (1) WO2015013690A1 (ar)
ZA (1) ZA201600145B (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011002836A (es) 2008-09-17 2011-04-28 Chiasma Inc Composiciones farmaceúticas y métodos de administración relacionados.
AU2017345720B2 (en) 2016-10-21 2023-07-27 Chiasma, Inc. Terlipressin compositions and their methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE399252B (sv) * 1976-05-24 1978-02-06 Ferring Ab Forfarande for framstellnign av antidiuretiskt verkande desamino-asparagin Ÿ4-d-argininŸ8-vasopressin
CA1246055A (en) * 1980-03-24 1988-12-06 Joseph H. Cort N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs
DK153883A (da) 1982-04-20 1983-10-21 Ceskoslovenska Akademie Ved Vasopressin-analoge
SE501677C2 (sv) * 1993-06-18 1995-04-10 Ferring Bv Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel
US5500413A (en) * 1993-06-29 1996-03-19 Ferring Ab Process for manufacture of 1-deamino-8-D-arginine vasopressin
CZ292131B6 (cs) 2000-02-16 2003-08-13 Ústav organické chemie a biochemie AV ČR Synthetické analogy Desmopressinu chráněné v C-terminální sekvenci proti karboxyamidasovému štěpení

Also Published As

Publication number Publication date
KR20160034943A (ko) 2016-03-30
SG11201600031RA (en) 2016-02-26
HUE035252T2 (en) 2018-05-02
US20190194257A1 (en) 2019-06-27
TW201536815A (zh) 2015-10-01
NZ716342A (en) 2021-03-26
LT3024829T (lt) 2017-12-27
HRP20180009T1 (hr) 2018-02-09
KR102198130B1 (ko) 2021-01-05
CN105492441A (zh) 2016-04-13
IL243730B (en) 2019-09-26
JP6387095B2 (ja) 2018-09-05
JP2016527255A (ja) 2016-09-08
CA2919208A1 (en) 2015-01-29
MY183429A (en) 2021-02-18
PH12016500044B1 (en) 2016-03-28
AU2014292860A1 (en) 2016-01-28
PL3024829T3 (pl) 2018-04-30
AU2014292860B2 (en) 2017-10-05
US10131692B2 (en) 2018-11-20
SI3024829T1 (en) 2018-01-31
MX2016000525A (es) 2016-04-07
ES2656039T3 (es) 2018-02-22
EP3024829B1 (en) 2017-11-08
MX363355B (es) 2019-03-21
US10745443B2 (en) 2020-08-18
EA201690219A1 (ru) 2016-11-30
DK3024829T3 (en) 2017-12-04
TWI640542B (zh) 2018-11-11
EP3024829A1 (en) 2016-06-01
EA029392B1 (ru) 2018-03-30
BR112016000436A2 (ar) 2017-07-25
CN105492441B (zh) 2019-09-10
BR112016000436B1 (pt) 2022-07-05
PH12016500044A1 (en) 2016-03-28
HK1218647A1 (zh) 2017-03-03
US20150307555A1 (en) 2015-10-29
PT3024829T (pt) 2017-12-18
ZA201600145B (en) 2020-01-29
IL243730A0 (en) 2016-04-21
RS56604B1 (sr) 2018-02-28
WO2015013690A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CL2017001288A1 (es) Agonistas parciales del receptor de insulina
PH12016500739A1 (en) Inhibitors of the fibrolast growth factor receptor
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
EA201290626A1 (ru) Устройство
PH12016500316A1 (en) Improved adenovirus formulations
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
GB201017345D0 (en) Receptor antagonists
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
EP3089432A4 (en) List generating device, list distribution device, received call processing device and program
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
CR20160136A (es) Compuestos heterocíclicos
CL2014001871A1 (es) Compuestos derivados de espiroindolina sustituidos, antagonistas del receptor de la hormona liberadora de gonadotropina (gnrh); y composicion farmaceutica que los comprende.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
PH12018501844A1 (en) Liraglutide in cardiovascular conditions
PH12016500044A1 (en) Vasopressin-2 receptor agonists
GB201312010D0 (en) Receptor Agonists
UA88242U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия
赵潇雨 Choose
UA90689U (uk) Комплексний протипаразитарний препарат "лактоверм"
MY163393A (en) Pharmaceutical formulations of telmisartan and process for preparing the same
IN2013CH00453A (ar)
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия
UA78463U (uk) Матеріал для термопар і термоелементів